Background: Neuroendocrine carcinoma is an uncommon histology for breast cancer.
Case report: Our patient underwent right quadrantectomy for a neuroendocrine carcinoma in 1984 and had a bone relapse 30 years later. After thorough pathological and immunohistochemical analysis the diagnosis was confirmed and HER2 amplification was observed. Here we discuss the management, rationale and results of HER2-targeted therapy in advanced neuroendocrine breast carcinoma.
Keywords: Breast carcinoma; Neuroendocrine carcinoma; Trastuzumab.